The FDA panel voted on seven peptides and recommended six. Here is what actually changed.

What happened

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee met to review seven peptides nominated for the 503A bulk drug substances list. The committee voted to recommend six of them: BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax. It voted against one, emideltide, the substance usually sold as DSIP.

The margins were tight. BPC-157 cleared on an 8 to 6 vote, and the rest of the yes votes landed in the same range. Emideltide failed 6 to 7.

The part that got least coverage matters most. FDA's review staff had evaluated all seven against the agency's standard criteria and recommended against every one of them, citing insufficient evidence to judge safety and effectiveness. The committee is made up of outside advisers, and it voted the other way. Reporting from NBC News and STAT also noted that a majority of the panelists who voted yes have professional ties to the peptide industry.

It is also worth knowing that this committee does not rubber-stamp peptides. It reviewed ipamorelin in October 2024 and CJC-1295, thymosin alpha-1, and AOD-9604 in December 2024, and voted against every one of them.

What a 503A listing is

This is the part that decides whether the vote means anything to you, so it is worth being precise.

Section 503A of the Federal Food, Drug, and Cosmetic Act covers compounding by state-licensed pharmacies, by licensed physicians, and in federal facilities. Under it, a drug cannot be compounded from any raw ingredient the compounder chooses. A bulk substance qualifies in one of three ways: it has a USP or NF monograph, or it is a component of an FDA-approved drug, or it appears on the 503A bulks list at 21 CFR 216.23.

That third route is what the committee was voting about. The list is short and deliberately hard to get onto. FDA evaluates a nominated substance on four things: how well the substance is chemically characterized, its safety, the evidence that it works for the proposed use, and how long and how widely it has actually been used in compounding.

Each of the seven nominations named a specific proposed use rather than general wellness use, and the evidence for that use is what FDA's reviewers assessed.

One more thing about the list itself. Getting on it clears one requirement, the ingredient. It does not make a finished compounded product lawful on its own, and entries can be narrower than the substance: several substances already on the list are limited to topical use only. So even a best-case outcome here could arrive with limits on form or route attached.

The four things this vote is not

It is not FDA approval. A substance on the 503A bulks list is a legal ingredient for a pharmacy to compound with. It has no approved label, no approved indication, no approved dose, and no FDA finding that it works. Approval is an entirely different process that none of these six has entered.

It is not binding. The Pharmacy Compounding Advisory Committee advises. FDA decides. The agency usually follows the committee, but it is not required to, and it has gone the other way before.

It is not in effect. Even if FDA agrees, adding a substance to 21 CFR 216.23 requires notice-and-comment rulemaking: a proposed rule, a public comment window, then a final rule. As of August 2026 none of the six appears in that regulation. Law firms advising compounding pharmacies have been blunt about it, telling clients these peptides still cannot be lawfully compounded and that FDA retains enforcement authority in the meantime.

It has nothing to do with research-chemical websites. The 503A list governs licensed compounding pharmacies filling patient-specific prescriptions written by a prescriber. A vial sold online labeled "for research use only" is outside that system entirely, and a favorable committee vote does not touch it, legitimize it, or say anything about what is in it.

The 2026 events people keep merging

Most of the confusion comes from stacking four different things into one story.

In February 2026, HHS announced an intent to move a set of peptides off FDA's Category 2 list, the list of bulk substances the agency had identified as posing significant safety risks.

In April 2026, FDA removed a group of those peptides from Category 2, on the stated basis that the nominations behind them had been withdrawn. FDA was explicit that removal from Category 2 does not by itself put a substance on the 503A bulks list or into Category 1, and in the same action it took GHK-Cu out of Category 1. Nor is it a retraction: FDA still publishes the safety concerns it had identified for substances that left the category this way. The April change moved these peptides into no category at all, waiting for review.

In May 2026, FDA reversed part of the April action. The nominator for GHK-Cu clarified that it had meant to withdraw only the injectable route, so on May 14 FDA put GHK-Cu, except for injectable routes of administration, back into Category 1. GHK-Cu therefore sits in Category 1 for non-injectable use only, and injectable GHK-Cu does not.

In July 2026, the committee voted. That is the step that could eventually lead to a listing, and it is only the first step.

Articles that describe February or April as "the FDA approved these peptides" are describing a category removal as if it were an approval. Articles that describe the July vote as "cleared for compounding" are describing a recommendation as if it were a rule.

Where the seven stand right now

Every row in that table says the same thing in the status column, which is the point. The vote moved a procedural step. It did not move any of these compounds' legal or evidentiary standing.

What happens next

FDA has to decide whether to act on the recommendation. If it chooses to, a proposed rule goes into the Federal Register and the public gets a comment period. A proposed rule is not a promise: it can be narrowed, delayed, or never finalized. There is no published deadline for any of it, and no way to read the July vote as a date.

FDA has said it will hold another committee meeting before the end of February 2027 to consider more peptides. The time and place have not been set.

If FDA does list some of these, the practical effect is narrow and specific: a compounder operating under 503A, which means a state-licensed pharmacy, a licensed physician, or a federal facility, could use that substance as an ingredient, under all the other 503A conditions. It would still not be an approved drug, there would still be no approved dosing, and a listing would not itself strengthen the evidence. A regulatory pathway opening is not the same as a question being answered.

Bottom line

Six peptides got a narrow, non-binding recommendation from a committee of outside advisers who disagreed with FDA's own review staff. Nothing became legal, nothing became approved, and no evidence changed. If you see a seller citing the July vote as proof that a product is now sanctioned, that is a marketing claim built on a procedural step, and it is the clearest signal you will get about how that seller handles the truth.

Go deeper:

• What FDA approved, WADA banned, and Cat 1 actually mean, the full label decoder
• The Honest Peptide Report Card, hype versus evidence on the most-searched compounds
• Educational only. Not legal or medical advice.